Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Non-Current Assets (2017 - 2025)

Dr Reddys Laboratories (RDY) has 8 years of Non-Current Assets data on record, last reported at $1.7 billion in Q1 2024.

  • For Q1 2024, Non-Current Assets rose 3994.17% year-over-year to $1.7 billion; the TTM value through Mar 2024 reached $1.7 billion, up 3994.17%, while the annual FY2024 figure was $1.7 billion, 3908.56% up from the prior year.
  • Non-Current Assets reached $1.7 billion in Q1 2024 per RDY's latest filing, up from $41.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $1.7 billion in Q1 2024 and bottomed at $10.1 million in Q1 2020.
  • Average Non-Current Assets over 5 years is $355.1 million, with a median of $32.7 million recorded in 2022.
  • Peak YoY movement for Non-Current Assets: rose 21.07% in 2021, then soared 3994.17% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $10.1 million in 2020, then increased by 21.07% to $12.2 million in 2021, then surged by 167.42% to $32.7 million in 2022, then rose by 25.38% to $41.0 million in 2023, then skyrocketed by 3994.17% to $1.7 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $1.7 billion in Q1 2024, $41.0 million in Q1 2023, and $32.7 million in Q1 2022.